Simulations Plus, Inc. (SLP) Q2 2026 Earnings Call Transcript

Simulations Plus hosted its Q2 FY2026 earnings call on April 9, 2026 with CEO Shawn O'Connor and CFO Will Frederick; an updated quarterly earnings presentation was posted on the company's investor website. Management emphasized forward-looking statements, risk disclosures, and availability of non-GAAP reconciliations, but the provided excerpt included no financial metrics, results or guidance.

Analysis

Simulations Plus sits at an inflection where regulatory acceptance of model‑informed drug development (MIDD) and incremental pharma headcount/time savings could drive outsized revenue stickiness if the company continues shifting perpetual licenses toward recurring SaaS and cloud consumption. If management can convert an incremental 20–30% of revenue to true subscription ARR within 12–24 months, consensus multiples for niche scientific software providers typically re‑rate by 3–5x EV/ARR as predictability and renewal visibility improve.

AI/LLM advances create a two‑edged sword: they lower the marginal cost of hypothesis generation for customers (downward pressure on small consulting engagements) while increasing demand for validated, auditable simulation engines for regulatory submissions — an area where incumbents with certification and documentation processes are advantaged. This dynamic implies faster revenue growth for validated platforms but potential near‑term pricing pressure on ad hoc services and new‑license ASPs (plausible 10–20% compression over 12–36 months if competition intensifies).

Key near‑term catalysts and risks are measurable: subscription ARR growth rate, gross margin expansion (compute mix vs license margin), concentration of top‑5 customers, and new contract backlog length. Major customer budget cuts or a high‑profile open‑source model obtaining regulatory acceptance would be a rapid negative catalyst (months), while a meaningful uplift in subscription mix or a bolt‑on AI/validation acquisition would be a re‑rating event over 3–12 months.

Key Decisions for Investors

• Long SLP equity (size 2–4% portfolio): accumulate on 10–20% post‑earnings pullbacks with a 12–24 month horizon. Target +40% upside if subscription ARR expands 20–30% and gross margins improve; set tactical stop at -25% to limit exposure to customer concentration risk.
• Directional options (12–18 month LEAP call spread): buy a 12–18 month LEAP call and finance by selling a nearer‑dated out‑of‑the‑money call to cap premium. Risk/reward ~3:1 if a subscription re‑rate occurs; keep position <=1% of NAV to limit theta/volatility decay.
• Hedge pair (reduce cyclicality): pair a long SLP with a modest short in biotech cyclical exposure (example: short 0.5x notional of IBB) to isolate software/validation upside versus broad R&D budget cyclicality. Expect this to outperform in scenarios where customers prioritize validated software over new molecule spend.
• Protective hedge ahead of earnings: buy 6–9 month puts sized to cap maximum drawdown (cost ~3–5% of long position). Use this if visibility into top‑customer renewals or subscription ARR growth is low — it’s a cheap insurance against a surprise revenue cadence miss.